British pharmaceutical giant GlaxoSmithKline (GSK.UK) sued Pfizer and BioNTech in US federal court, accusing both companies of infringing GSK patents related to RNA (mRNA) vaccine technology, used in the COVID-19 vaccines. According to GlaxoSmithKline, the company developed those innovations more than a decade before COVID-19 pandemic. What's more, GSK claims that it bought all rights to the developed since 2008 innovation technology after acquiring Novartis in 2015.
- Pfizer spokesperson said that the company will defend all allegations from GSK, but BioNTech declined to comment. According to GSK patents provided the foundational technology and will try to capitalize on it. Also, Moderna sued Pfizer in 2022 over patent royalties. Last year, Pfizer Covid-19 sales were $11.2 billion (Comirnaty).
- Moderna earned $6.7 billion in revenue from the Spikevax, but sales of both vaccines declined on YoY basis. GSK asked the court for an unspecified amount of monetary damages from Pfizer and BioNTech over the patent-licensing fee. Today also British conglomerate WPP blamed Pfizer for loss and 1.6% YoY revenue fall in Q1. Shares of GSK gained slightly today, rising 0.15%.
Pfizer (PFE.US) and BioNTech (BNTX.US) on D1 interval
From the fall of 2021 Pfizer is one of the weakest companies among S&P500 index and sales of Covid-19 vaccines is slowing.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appSource: xStation5
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.